Adial Pharmaceuticals entered 2026 as a micro-cap addiction biotech running low on runway. The balance sheet at March 31 showed roughly $4.6 million in cash, a going-concern qualification, and enough liquidity to fund operations only into the second half of the year - all centered on AD04, a genetically targeted serotonin-3 antagonist for alcohol use disorder that had completed a Phase 3 trial but lacked the money to launch the next one. The stock at that moment was a countdown.
Then the company changed what it is. On June 11 it acquired Azora Therapeutics, a private ulcerative-colitis biotech spun out of Stanford, in a transaction that handed effective control of Adial to Azora's investors and a syndicate of new backers, while injecting up to $64 million in gross proceeds. The combined company's lead program is no longer AD04; it is AT177, a colon-targeted aryl hydrocarbon receptor agonist in IND-enabling studies, with Adial's addiction pipeline pushed to a supporting role. Pre-merger Adial shareholders are left with roughly 7.7% of the fully diluted company after the scheduled approvals.
The thesis is not about the old AUD story anymore. It is about whether a freshly capitalized, control-shifted biotech can move AT177 through the clinic fast enough to earn its financing, with the second half of the new money and the value of the deal riding on a single preclinical molecule. What changed this period is that the company bought itself time and a new asset at the cost of the original holders' economic interest. What decides the case is AT177's path to the clinic and whether the transaction's scheduled approvals come off as structured.